25%-69% 5-year survival rate.
Comprise about 10% of pulmonary carcinoids and are characterized by increased mitotic activity, nuclear pleomorhphism.
Most patients with thoracic lymph nodes metastases develop systemic disease at a median of 17 months after diagnosis.